Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Hidalgo (Saarbrücken, Germany), J. Perez-Gil (Madrid, Spain), C. Lehr (Saarbrücken, Germany). Pulmonary surfactant: a Trojan Horse to deliver anti-TB drugs. 465

Member's Comments

No comment yet.

Related content which might interest you: Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Development of new drug products for inhalation therapy of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 652s Year: 2004 Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Drug loaded liposomes of mesalamine incorporated into disease responsive microgels (Micro) for treating allergic asthma: An approach using smart drug delivery system Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Effect of antituberculosis treatment on cardiopulmonary responses to exercise in pulmonary tuberculosis Source: International Congress 2016 – Clinical exercise physiology in health and disease Year: 2016 Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020 Therapeutic strategies in pneumonia: going beyond antibiotics Source: Eur Respir Rev 2015; 24: 516-524 Year: 2015 Response of pulmonary tuberculoma to anti-tuberculosis treatment Source: Eur Respir J 2003; 22: Suppl. 45, 521s Year: 2003 Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017 Year: 2018 Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017 Year: 2018 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Availability of anti-tuberculosis drugs in Europe Source: Eur Respir J 2012; 40: 500-503 Year: 2012 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Treatment of patients with extensive TB and concomitant bronchial lesions with some anti-TB drugs delivered via nebulizer Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013 Inhaled antibiotics: a new tool? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009